A UK key opinion leader perspective: Navigating the immunological and logistical transformation brought by stem cell‐derived islets for the treatment of type 1 diabetes
Diabetic Medicine · 2026
DOI: 10.1111/dme.70230 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetic Medicine, 2026. Verfasst von Thomas Strakosch und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cell and Gene Therapy Catapult (CGTC), London, UK. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Stem Cell Transplantation, Islets of Langerhans. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Steve Morgan Foundation Type 1 Diabetes Grand Challenge" by Diabetes UK, Breakthrough T1D and SMF, Leona M. and Harry B. Helmsley Charitable Trust, Chief Scientist Office.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To explore UK key‐opinion leader perspectives on the future role of stem cell‐derived islets (sc‐islets) in islet transplantation for people with type 1 diabetes (T1D).
Methods
Four UK‐based key‐opinion leaders evaluated current limitations of donor islet transplantation and reviewed emerging evidence, clinical pathways and logistical considerations for sc‐islet transplantation, including alternative delivery sites and implications for kidney transplantation strategies.
Results
Conventional islet transplantation is constrained by donor scarcity, variable graft quality and lifelong immunosuppression, with associated risks of infection, malignancy and calcineurin inhibitor (CNI) nephrotoxicity. Stem cell‐derived islets, generated from human embryonic and induced pluripotent stem cells, provide a scalable and standardised alternative. Early investigational products, including Zimislecel (VX‐880), demonstrate potential for insulin independence and may offer an alternative to simultaneous pancreas–kidney (SPK) transplantation. Strategies to reduce or eliminate systemic immunosuppression particularly CNI immunosuppression through local immunomodulation, gene editing and encapsulation technologies may further broaden access. Ethics, infrastructural and economic considerations remain central to equitable implementation.
Conclusion
Stem cell–derived islets may redefine islet transplantation for T1D by enabling more scalable, less invasive and sustainable therapeutic pathways while maintaining access to technological diabetes management options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cell and Gene Therapy Catapult (CGTC), London, UK.
- BHF Centre for Cardiovascular Science, Institute for Neuroscience and Cardiovascular Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
ORCID-Profile: Thomas Strakosch, Shareen Forbes
Förderung
- "Steve Morgan Foundation Type 1 Diabetes Grand Challenge" by Diabetes UK, Breakthrough T1D and SMF
- Leona M. and Harry B. Helmsley Charitable Trust
- Chief Scientist Office
Zitieren
APA
Strakosch, T., & Forbes, S. (2026). A UK key opinion leader perspective: Navigating the immunological and logistical transformation brought by stem cell‐derived islets for the treatment of type 1 diabetes. Diabetic Medicine. https://doi.org/10.1111/dme.70230
Vancouver
Strakosch T, Forbes S. A UK key opinion leader perspective: Navigating the immunological and logistical transformation brought by stem cell‐derived islets for the treatment of type 1 diabetes. Diabetic Medicine. 2026. doi:10.1111/dme.70230
BibTeX
@article{Strakosch2026,
author = {Strakosch, Thomas and Forbes, Shareen},
title = {A UK key opinion leader perspective: Navigating the immunological and logistical transformation brought by stem cell‐derived islets for the treatment of type 1 diabetes},
journal = {Diabetic Medicine},
year = {2026},
doi = {10.1111/dme.70230}
}
EUVIMED